MMCAP-Generic/Multisource Pharmaceuticals & Over the Counter Products

The State of South Dakota, through MMCAP (Multistate Contracting Alliance Program), is seeking proposals for Generic/Multisource Pharmaceuticals and Over the Counter Products under Reference Number 33846. This Request for Proposal (RFP) seeks pharmaceutical vendors capable of providing a comprehensive range of generic and multisource pharmaceutical products and over-the-counter medications. Interested vendors must download RFP documents from the Office of State Procurement (OSP) website by following a specific five-step process that includes searching for the reference number, downloading documents, and submitting contact information. The solicitation requires vendors to submit their complete response by March 8, 2024, at 2:00 p.m. Central Time. Potential bidders with questions about the solicitation are instructed to email MMCAP_Infuse.RFP@state.mn.us for clarification. The procurement appears designed to establish a comprehensive pharmaceutical supply contract that can support multiple state and local healthcare entities.

While specific set-aside designations are not explicitly detailed in the provided documentation, the RFP suggests a competitive procurement process open to pharmaceutical suppliers and distributors. The solicitation does not indicate specific restrictions on organizational types, though standard procurement protocols typically require vendors to meet basic qualifications such as licensing, financial stability, and product compliance. No incumbent vendors or existing contract details are mentioned in the current documentation. The procurement appears focused on establishing a multistate contract for pharmaceutical products, which implies potential significant contract value, though exact budget ranges are not specified. Vendors should anticipate a comprehensive evaluation process that likely considers factors such as product availability, pricing, distribution capabilities, and compliance with pharmaceutical regulations. The contract's multistate nature through MMCAP suggests a substantial opportunity for selected vendors to provide pharmaceutical products across multiple jurisdictions.